



Compiled by Nancy J. Ciancaglini

ACORN™ (Memphis, Tenn.)

Accelerated Community Oncology Research Network, Inc. (ACORN), a national oncology-focused Contract Research Organization (CRO) and clinical trial network, named **Tara Webb** as Senior Director of Business Development. Webb was formerly Senior Director, Business Development for i3 Statprobe.

ADVENTRX PHARMACEUTICALS Inc. (San Diego, Calif.)

Adventrx announced a restructuring and a reduction of its staff by 27 percent. Chief Executive Officer (CEO) and President **Evan M. Levine** resigned his position to pursue other opportunities. **Mark Erwin**, previously Vice President of Commercialization, was promoted to Senior Vice President, Operations. The company also ended its employment relationship with its Chief Scientific Officer, Vice President, Medical Affairs and Vice President, Research and Development.

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (Alexandria, Va.)

John V. Cox, DO, MBA, FACP, was named as the new Editor-in-Chief of the *Journal of Oncology Practice*, ASCO's practice management journal.

ARIAD PHARMACEUTICALS INC. (Cambridge, Mass.)

Maria E. Cantor was appointed to the newly created position of Vice President, Corporate Communications and Investor Relations. She was most recently Senior Director of Corporate Communications at Genzyme Corporation.

ASSOCIATION OF COMMUNITY CANCER CENTERS (Rockville, Md.)

ACCC's 2008 Clinical Research Award was presented to **Donald L. Morton, MD**, during the 25th Oncology Economics Conference in San Francisco in September. Dr. Morton is Chief of the Melanoma Program and Director of the Surgical Oncology Fellowship Program at the John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California.

CELLEX THERAPEUTICS Inc. (Needham, Mass.)

AVANT Immunotherapeutics, Inc. changed its name to Celldex Therapeutics, Inc. and will be listed on the NASDAQ under a new ticker symbol, "CLDX." **Anthony S. Marucci**, who had served as interim President and CEO, was named President and CEO. The two companies merged in early 2008.

CELL GENESYS Inc. (South San Francisco, Calif.)

Shares sank 74 percent in mid-October when the company halted a second trial of its experimental prostate cancer vaccine, GVAX, due to poor results. Cell Genesys said it would explore stra-

tegic alternatives, including sale and liquidation, and would cut 75 percent of its current workforce. Chief Medical Officer **Robert Dow** was terminated and more staff reductions are expected in the first half of 2009.

CELL THERAPEUTICS Inc. (Seattle, Wash.)

Christina A. Waters, PhD, MBA, was named President of CTI Europe, based in Bresso, Italy. She was most recently President and Chief Operating Officer (COO) of Tyr Pharma.

CYTOKINETICS Inc. (South San Francisco, Calif.)

The company said it would cut about 29 percent of its workforce and stop all oncology-related research to instead focus on its muscle biology program. Cytokinetics does plan, however, to continue with the development of three cancer treatments currently in its pipeline.

GLAXOSMITHKLINE PLC (London, England)

The British drugmaker plans to consolidate its drug discovery and drug development teams into one unit and create a new cancer-focused R&D group. **Paolo Paoletti**, Glaxo's Senior Vice President of Oncology, will head the new group, GSK Oncology, which will be based in Philadelphia.

IMCLONE SYSTEMS Inc. (New York, NY)

The Erbitux® maker's buyout saga, featuring an unsolicited bid from Bristol-Myers Squibb that rose from \$60 to \$62 a share, ended when mystery bidder Eli Lilly & Co. announced that it would acquire ImClone in an all cash tender offer for \$70 a share, or \$6.5 billion. The deal is expected to close late this year or in early 2009. The transaction will be worth approximately \$1 billion in cash to Bristol-Myers since it owns 16.6 percent of all outstanding shares of ImClone, and the company will become Lilly's new marketing partner in North America for Erbitux.

IMMUNOGEN Inc. (Waltham, Mass.)

Daniel M. Junius, who was named President and COO earlier this year, will become President and CEO, effective January 1, 2009. **Mitchel Sayare, PhD**, Chairman and CEO for the past 22 years, will continue as Chairman of the Board and as a director.

THE INTERNATIONAL MYELOMA FOUNDATION (North Hollywood, Calif.)

IMF announced that Revlimid®, Celgene's oral drug for multiple myeloma, won the Prix Galien USA 2008 Award for Special Therapeutic Development. The Prix Galien is the industry's highest accolade for pharmaceutical research and development (R&D).

MATTSON JACK GROUP Inc. (St. Louis, Mo.)

MattsonJack, a business analytics leader for the pharmaceutical and healthcare industries, launched CancerNFluence®, a comprehensive database of peer-nominated physicians in the U.S. and Western Europe who influence treatment decisions in cancer.

MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY (Cambridge, Mass.)

Two new executives joined the company: **Claire Thom, PharmD**, was named as Senior Vice President, Portfolio Management and **Isabelle Mercier** was named as Vice President, Marketing for Millennium's commercial organization.

Thom previously directed global therapeutic area strategies for the oncology, urology and gynecology franchises of Takeda Pharmaceutical Company in Japan. Mercier most recently served as Vice President of Taxotere Marketing at sanofi-aventis.

NOVACEA INC. (South San Francisco, Calif.)

Novacea will be acquired by Transcept Pharmaceuticals, Inc., a privately-held company specializing in prescription sleep medicine and psychiatry drugs, in an all-stock deal. Novacea's executive officers will resign and Transcept's management will take charge of the new combined company, Transcept Pharmaceuticals. The deal is expected to close in late 2008 or early 2009.

NOVARTIS AG (Basel, Switzerland)

In a restructuring announced when it reported third quarter earnings and a reshuffling of key management in three of its business units, **David Epstein** was tapped to lead a new unit focusing on innovative molecular diagnostics, effective on December 1. Epstein already heads the Oncology Business Unit in the Pharmaceuticals Division.

PDL BIOPHARMA Inc. (Redwood City, Calif.)

Former Biogen Idec executive **Faheem Hasnain** will become President and CEO of Facet Biotech Corporation, the spin-off of PDL's biotechnology business, when the transaction closes at the end of 2008. Hasnain had been at Biogen Idec as Executive Vice President of the Oncology/Rheumatology Strategic Business Unit.

PENN STATE HERSHEY CHILDREN'S HOSPITAL (Hershey, Pa.)

The Four Diamonds Fund, whose mission is to conquer childhood cancer by assisting children treated at Penn State Hershey Children's Hospital, has created a \$5 million endowment for a Pediatric Cancer Experimental Therapeutics Program to speed the accessibility of new cancer therapies into the clinical trial setting from the lab. The program's director has yet to be appointed.

PFIZER Inc. (New York, N.Y.)

Mace L. Rothenberg, MD, was named as Senior Vice President, Clinical Development and Medical Affairs for Pfizer's Oncology Business Unit. Dr. Rothenberg joined Pfizer from Vanderbilt in Nashville, Tennessee, where he was Professor of Medicine at the Vanderbilt University Medical Center and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center.

PHARMACYCLICS Inc. (Sunnyvale, Calif.)

President and CEO **Richard A. Miller** left in October, along with four Board members and Chief Financial Officer (CFO) **Leiv Lea. Robert W. Duggan**, a remaining Board member, will become interim CEO until a permanent replacement is found for Miller. The company didn't give any reasons for the departures. Both Miller and Lea will serve as consultants through the end of 2008.

PHARMATECH Inc. (Denver, Colo.)

Matthew B. Wiener, PharmD, the CEO of Pharmatech, a Research Management Organization (RMO) focusing on oncology clinical trials, was recently awarded the Outstanding Cancer Leadership Award from the Colorado Cancer Coalition. The award honored Dr. Wiener for his development of the Just-In-Time (JIT) enrollment methodology, which is meant to increase enrollment in cancer clinical trials for rare disease indications.

SEATTLE GENETICS Inc. (Bothell, Wash.)

The company announced the following new hires: **Elaine Waller, PharmD**, joined as Senior Vice President, Regulatory Affairs and **Christopher Pawlowicz** joined as Senior Vice President, Human Resources. **Jonathan Drachman, MD**, was promoted to President, Early Clinical Development, from his former position as Senior Medical Director.

TAKEDA SAN FRANCISCO Inc. (San Francisco, Calif.)

Gregory Landes, PhD, joined Takeda San Francisco as Vice President of Antibody Research. Dr. Landes previously held similar executive positions involving antibody drug discovery and development with Lexicon Pharmaceuticals, Abgenix, Inc. and Genzyme Corporation.

UC DAVIS CANCER CENTER (Sacramento, Calif.)

The Cancer Center launched the UC Davis Cancer Care Network, formalizing its collaborations with five hospital-based cancer centers in Northern and Central California that are dedicated to providing quality patient care in community settings. **Scott Christensen, MD**, a UC Davis Associate Professor of Hematology and Oncology, was named as the Network's Medical Director.

US ONCOLOGY (Houston, Tex.)

The company launched Innovent Oncology, a service division providing oncologists and health plans with a first-time opportunity to work together through integrated programs designed specifically for the complexity of cancer care.

US Oncology also announced that **Stephen Smith**, formerly Senior Vice President, Global Oncology at INC Research, had joined as Vice President/General Manager Research and Personalized Science Services. Smith will oversee the US Oncology Research Network, which provides research management services to oncology practices and sites throughout the nationwide US Oncology Network.

NIC